Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Sold by Jacobs Levy Equity Management Inc.

Jacobs Levy Equity Management Inc. decreased its stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) by 37.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 576,042 shares of the biotechnology company's stock after selling 339,467 shares during the period. Jacobs Levy Equity Management Inc. owned 0.81% of Aclaris Therapeutics worth $1,429,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Assenagon Asset Management S.A. increased its position in Aclaris Therapeutics by 113.9% during the fourth quarter. Assenagon Asset Management S.A. now owns 397,362 shares of the biotechnology company's stock worth $985,000 after buying an additional 211,585 shares during the period. Peapod Lane Capital LLC purchased a new position in shares of Aclaris Therapeutics during the fourth quarter worth approximately $1,003,000. JPMorgan Chase & Co. increased its holdings in shares of Aclaris Therapeutics by 942.0% in the 4th quarter. JPMorgan Chase & Co. now owns 88,320 shares of the biotechnology company's stock valued at $219,000 after acquiring an additional 79,844 shares during the period. Marshall Wace LLP purchased a new stake in Aclaris Therapeutics in the 4th quarter valued at $6,532,000. Finally, Raymond James Financial Inc. acquired a new stake in Aclaris Therapeutics during the 4th quarter worth $383,000. 98.34% of the stock is owned by hedge funds and other institutional investors.

Aclaris Therapeutics Stock Performance

NASDAQ:ACRS traded down $0.02 during mid-day trading on Thursday, reaching $1.28. The stock had a trading volume of 86,324 shares, compared to its average volume of 1,179,026. The firm has a market capitalization of $138.06 million, a price-to-earnings ratio of -2.45 and a beta of 0.42. The business has a 50 day simple moving average of $1.34 and a 200 day simple moving average of $2.21. Aclaris Therapeutics, Inc. has a twelve month low of $0.95 and a twelve month high of $5.17.

Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($0.12) earnings per share for the quarter, topping analysts' consensus estimates of ($0.19) by $0.07. Aclaris Therapeutics had a negative return on equity of 40.26% and a negative net margin of 136.65%. As a group, sell-side analysts expect that Aclaris Therapeutics, Inc. will post -0.82 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ACRS. Scotiabank reduced their target price on shares of Aclaris Therapeutics from $15.00 to $9.00 and set a "sector outperform" rating for the company in a report on Friday, May 9th. Cantor Fitzgerald initiated coverage on Aclaris Therapeutics in a research note on Tuesday, March 18th. They set an "overweight" rating for the company. HC Wainwright reaffirmed a "buy" rating and set a $16.00 price objective (down from $20.00) on shares of Aclaris Therapeutics in a research report on Wednesday, May 14th. Finally, Wall Street Zen downgraded Aclaris Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, February 8th. One investment analyst has rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $10.00.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.